Abstract
Previously we have shown that the neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors and assumed that the pharmacological effects of CPG are associated with the brain neurotrophic factor. In this paper, we have first demonstrated that DNQX, an inhibitor of AMPA receptors, and K252A, an ihibitor of Trk receptors, prevented the anxiolytic effect of CPG, which confirms the formulated hypothesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Gudasheva, T.A., Ostrovskaya, R.U., Maksimova, F.V., et al., Proline-based topologic pyracetam analogs and their nootropic activity, Pharm. Chem. J., 1989, vol. 23, pp. 203–208.
Gudasheva, T.A., Boyko, S.S., Akparov, V.Kh., et al., Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain, FEBS Lett., 1996, vol. 391, pp. 149–152.
Fan, D., Krishnamurthi, R., Harris, P., et al., Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients, Ann. Clin. Transl. Neurol., 2019, vol. 6, no. 4, pp. 669–677.
Guan, J. and Gluckman, P.D., IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions, Br. J. Pharmacol., 2009, vol. 157, no. 6, pp. 881–891. https://doi.org/10.1111/j.1476-5381.2009.00256.x
Gudasheva, T.A., Konstantinopol’skii, M.A., Ostrovskaya, R.U., and Seredenin, S.B., Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test, Bull. Exp. Biol. Med., 2001, vol. 131, no. 5, pp. 464–466.
Ferro, J.N., de Aquino, F.L., de Brito, R.G., et al., Cyclo-Gly-Pro, a cyclic dipeptide, attenuates nociceptive behaviour and inflammatory response in mice, Clin. Exp. Pharmacol. Physiol., 2015, vol. 42, no. 12, pp. 1287–1295. https://doi.org/10.1111/1440-1681.12480
Garibova, T.L., Gudasheva, T.A., and Seredenin, S.B., A new component in the mechanism of regulation of endogenous depressive-like states, Dokl. Biochem. Biophys., 2019, vol. 488, no. 1, pp. 324–326. https://doi.org/10.1134/S1607672919050107
Gudasheva, T.A., Grigoriev, V.V., Koliasnikova, K.N., et al., Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors, Dokl. Biochem. Biophys., 2016, vol. 471, no. 1, pp. 387–389. https://doi.org/10.1134/S160767291606003X
Ahmed, A.H. and Oswald, R.E., Piracetam defines a new binding site for allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors, J. Med. Chem., 2010, vol. 53, no. 5, pp. 2197–2203. https://doi.org/10.1021/jm901905j
Gudasheva, T.A., Koliasnikova, K.N., Antipova, T.A., and Seredenin, S.B., Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells, Dokl. Biochem. Biophys., 2016, vol. 469, no. 1, pp. 273–276. https://doi.org/10.1134/S1607672916040104
Jourdi, H., Hsu, Y.T., Zhou, M., et al., Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation, J. Neurosci., 2009, vol. 29, no. 27, pp. 8688–8697. https://doi.org/10.1523/JNEUROSCI.6078-08.2009
Aguado-Llera, D., Canelles, S., Fernandez-Mendivil, C., et al., Improvement in inflammation is associated with the protective effect of Gly-Pro-Glu and cycloprolylglycine against Aβ-induced depletion of the hippocampal somatostatinergic system, Neuropharmacology, 2019, vol. 151, pp. 112–126. https://doi.org/10.1016/j.neuropharm.2019.04.008
Mao, Q.Q., Huang, Z., Zhong, X.M., Xian, Y.F., and Ip, S.P., Brain-derived neurotrophic factor signalling mediates the antidepressant-like effect of piperine in chronically stressed mice, Behav. Brain Res., 2014, vol. 261, pp. 140–145. https://doi.org/10.1016/j.bbr.2013.12.020
Rial, D., Takahashi, R.N., and Morato, G.S., Aniracetam and DNQX affect the acquisition of rapid tolerance to ethanol in mice, Pharmacol. Biochem. Behav., 2009, vol. 92, no. 1, pp. 32–38. https://doi.org/10.1016/j.pbb.2008.10.006
Funding
This work was supported by the Russian Foundation for Basic Research (project no. 20-015-00102 “Identification of the Role of Glutamatergic and BDNFergic Mechanisms in the Pharmacological Effects of the Neuropeptide Cycloprolylglycine”).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest. The authors declare that they have no conflict of interest.
Statement on the welfare of animals. In experiments, we complied with the requirements formulated in Order no. 199 of the Ministry of Health of the Russian Federation “On Approving the Rules of Good Laboratory Practice” and in the Decision of the EEC Council no. 81 “On Approving the Rules of Good Laboratory Practice of the Eurasian Economic Union in the Sphere of Medicines.” All manipulations with animals were approved by the Bioethical Commission of the Zakusov Research Institute of Pharmacology.
Additional information
Translated by M. Batrukova
Rights and permissions
About this article
Cite this article
Gudasheva, T.A., Povarnina, P.Y., Koliasnikova, K.N. et al. The Anxiolytic Effect of the Neuropeptide Cycloprolylglycine Is Mediated by AMPA and TrkB Receptors. Dokl Biochem Biophys 493, 190–192 (2020). https://doi.org/10.1134/S1607672920040067
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1607672920040067